-
Salix Pharmaceuticals (SLXP) Gets Overweight From Piper Jaffray
Tuesday, July 13, 2010 - 2:29pm | 102Read More...David Amsellem and Michael Dinerman, analysts at Piper Jaffray, have given an Overweight rating to Salix Pharmaceuticals (NASDAQ: SLXP), a specialty pharmaceutical company dedicated to treatment of a variety of gastrointestinal diseases. The target price is at $58.00, and the stock has been...
-
Impax Weakness Overblown, Cash Still Flowing; Piper Jaffray (IPXL)
Tuesday, July 6, 2010 - 8:15am | 194Read More...Impax Laboratories (NASDAQ: IPXL) has been hit hard in the past week, but Piper Jaffray analysts David Amsellem and Michael Dinerman think that this is mostly due to general market weakness. There are also concerns about stagnant market share for its Adderal XR (AXR) generic. Impax's AXR generic...
-
Piper Jaffray Maintains Overweight Rating On Salix Pharmaceuticals, Ltd. (SLXP)
Wednesday, June 2, 2010 - 2:51pm | 99Read More...Analysts David Amesellem and Michael Dinerman at Piper Jaffray have maintained their Overweight rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Analysts say that prescription (Rx) data since the late March FDA approval shows a clear acceleration in Rx growth. Analysts believe that the strong...
-
Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating
Thursday, March 25, 2010 - 10:15am | 175Read More...Piper Jaffray analysts David Amsellem and Michael Dinerman reiterated their Overweight rating and $58 price target for shares of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP). The statement came after the Food and Drug Administration (FDA) approved Salix Pharmaceuticals' 550 mg dose of Xifaxan (...
